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Statement of findings
An inception cohort of 238 patients having peripheral joint synovitis of less than 12 months
duration was evaluated clinically and followed prospectively for 1 year to determine the
clinical significance of a number of rheumatoid arthritis (RA) associated autoantibodies.
Serum samples collected at the time of the initial evaluation were tested for rheumatoid
factor (RF) and antibodies to Sa (anti-Sa), RA-33, (pro)filaggrin [antifilaggrin antibody
(AFA)], cyclic citrullinated peptide (anti-CCP), calpastatin, and keratin [antikeratin antibody
(AKA)]. RF had a sensitivity of 66% and a specificity of 87% for RA. Anti-Sa, AFA, and
anti-CCP all had a specificity of more than 90%, but a sensitivity of less than 50% for this
diagnosis. Overall, there was a high degree of correlation between AFA, AKA, anti-Sa or
anti-CCP, this being highest between anti-Sa and anti-CCP (odds ratio, 13.3; P<0.001). Of
the 101 patients who were positive for at least one of these four autoantibodies, 57% were
positive for only one. Finally, anti-Sa identified a subset of predominantly male RA patients
with severe, erosive disease. Anti-Sa, AFA and anti-CCP are all specific for early RA but,
overall, have little additional diagnostic value over RF alone. Although these antibodies may
preferentially recognize citrullinated antigens, the modest degree of concordance between
them in individual patient sera suggests that it is unlikely a single antigen is involved in
generating these responses.
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Introduction: A spectrum of autoantibodies is now known to
be specifically associated with RA. There continues to be
uncertainty as to what stage of the disease each of these
autoantibodies develop, and whether they are associated with
unique clinical features.
Aims: To help address these questions, a spectrum of
autoantibodies known to be associated with RA in a cohort of
patients with early synovitis was evaluated.
Methods: An inception cohort of 238 patients having
peripheral joint synovitis of less than 12 months duration was
evaluated clinically then followed prospectively for 1 year.
Patients were classified as having RA on the basis of fulfilling
the 1987 criteria. Serum samples collected at the time of the
initial evaluation were tested for anti-Sa and anti-RA-33 using
immunoblotting, and to (pro)filaggrin (AFA), anti-CCP, and
calpastatin (anti-RA-1) using enzyme-linked immunosorbent
assay techniques. AKA were detected using immuno-
flurescence on human epidermal tissue. RF was tested by
nephelometry. HLA-DRB1 alleles were determined using
sequence specific primers. Initial and 1 year radiographs were
evaluated for the presence of erosions.
Results: Of the 238 patients with synovitis of recent onset in the
cohort, 106 (45%) met RA criteria, 102 (96%) of whom met the
criteria on their initial visit. Diagnoses in the remaining patients
included 22 (9%) with reactive arthritis, 14 (6%) with psoriatic
arthritis or another form of spondylarthropathy, 11 (5%) with
another well-defined rheumatic diagnosis, and 85 (36%) with
undifferentiated arthritis. The RA patients were significantly older
than the nonRA patients (46±13 versus 39±13; P<0.001),
had higher mean swollen joint count (13.8±9.7 versus 2.3±2.3;
P<0.001), and higher C-reactive protein (CRP) level (1.9±1.9
versus 1.6±2.4; P<0.01). Table 1 summarizes the prevalence
of the various RA associated antibodies in patients diagnosed as
having RF-positive (RF+) RA, RF-negative (RF–) RA, and nonRA.
Regarding the characteristics of these tests, RF had the highest
sensitivity at 66%, and all the other antibodies individually were
less than 50% sensitive. AFA, anti-Sa, anti-CCP were greater
than 90% specific for RA, while RF and AKA were 80–90%
specific, and anti-RA-33 and anti-RA-1 was not specific for this
diagnosis. The data further indicate that adding any one of AFA,
AKA, anti-Sa, or anti-CCP to RF increases the specificity for RA
from 80 to 90%. In the absence of RF, the presence of one or
more of these antibodies carried a sensitivity of only 31% for
RF– RA, with anti-Sa being the most specific at 98%. Overall,
there was a high degree of correlation between AFA, AKA,
anti-Sa or anti-CCP, this being highest between anti-Sa and
anti-CCP (odds ratio, 13.3; P<0.001). Despite this high level of
correlation, of the 101 patients who were positive for at least one
of these four autoantibodies, 57% were positive for only one,
suggesting considerable variability in individual reactivity
patterns.
RA has been shown in multiple populations to be associated
with HLA-DRB1 alleles encoding for the shared epitope (SE).
In this study, as illustrated in Table 2, the presence of each of
these autoantibodies was significantly associated with having
two shared epitope alleles, even when only the RA patients
were considered.
Patients with anti-Sa antibodies were predominantly male
(61% versus 28%; P<0.01), had significantly higher swollen
joint counts (18±12 versus 13±9; P=0.02), and higher CRP
levels (2.6±3mg/dl versus 1.6±1.4mg/dl; P=0.03) at the
initial visit. Despite subsequently being treated with significantly
higher doses of prednisone (4.8±6.0mg/day versus
1.8±3.3mg/day;  P<0.01), and more disease modifying
antirheumatic drug therapy (1.4±0.8 versus 0.9±0.7 disease
modifying antirheumatic drugs; P<0.01), the anti-Sa-positive
RA patients had a higher frequency of erosions than the rest of
the RA patients (60% versus 33%; P=0.03). Neither RF nor
SE were associated with the disease severity measures, and
analyses evaluating all the other autoantibodies failed to reveal
a similar trend.
Synopsis
Table 1
Presenting clinical features and prevalence of autoantibodies
in rheumatoid factor positive rheumatoid arthritis (RF+ RA),
RF-negative RA (RF– RA), and nonRA patients
RF+ RA RF– RA NonRA
(n = 70) (n = 36) (n = 132)
Age 47 ± 12 44 ± 14 39 ± 13*
Female 44 (63) 27 (75) 87 (66)
Swollen joint count 13 ± 9 16 ± 10 2 ± 3*
CRP level 1.9 ± 1.9 1.9 ± 2.1 1.6 ± 2.4
Multiple erosions 12 (17) 7 (19) 7 (5)*
RF 70 (100) 0 17 (13)
ANA 25 (36) 10 (28) 30 (23)
ds-DNA 0 0 3 (2)
Anti-SSA 5 (7) 2 (6) 7 (5)
Anti-SSB 2 (3) 1 (3) 2 (2)
Anti-RNP 3 (4) 0 3 (2)
Anti-Sm 0 0 2 (2)
AFA 32 (46)† 3 (8)  9 (7)
Anti-Sa 18 (26)† 5 (14)‡ 3 (2)
Anti-CCP 38 (54)† 5 (14) 12 (9)
AKA 26 (37)† 1 (3) 21 (16)
Anti-RA-1 23 (33) 10 (28) 49 (37)
Anti-RA-33 2 (2) 0 1 (1)
All values represent either number of patients (%), or means ±
standard deviations. * P < 0.01 compared with RA patients; † P < 0.01
compared with RF– RA and nonRA; ‡ P < 0.01 compared with nonRA.
CRP, C-reactive protein; ANA, antinuclear antibodies; AFA,
antifilaggrin antibody; RNP, ribonucleoprotein; CCP, cyclic citrullinated
peptide; AKA, antikeratin antibody.Arthritis Research    Vol 2 No 3 Goldbach-Mansky et al
Discussion: Despite a well-documented lack of specificity, RF
continues to be a central part of the definition of RA, primarily
because of its favorable sensitivity profile. In our cohort, RF had a
sensitivity of 66%, a specificity of 87%, and an overall accuracy
of 78% for the diagnosis of RA. AFA, anti-Sa, anti-CCP were all
highly specific for this diagnosis, and when any of them were
present in conjunction with RF, the specificity for RA approached
100%. Potentially of more importance to the clinician is the
diagnostic value of these antibodies when RF is not detectable.
Our data indicate that only 31% of RF– RA patients had any of
AKA, AFA, anti-Sa or anti-CCP, and that anti-Sa was the most
specific for this diagnosis. This modest level of sensitivity
suggests that testing for this spectrum of autoantibodies carries
little advantage over RF alone in diagnosing early RA.
AFA, AKA, and antiperinuclear factor (APF) have all been
proposed to identify a common antigen present in the skin
protein (pro)filaggrin. It has continued to be puzzling why a skin
antigen would be targeted relatively specifically in a disorder
that is primarily articular. A potential explanation for this may
relate to the demonstration that citrulline appears to be an
essential constituent of the antigenic determinants recognized
by AKA, APF, and AFA. The citrulline rich (pro)filaggrin
molecule makes an ideal substrate for detecting this reactivity.
Moreover, the Sa antigen, which, unlike (pro)filaggrin, is
detectable in rheumatoid synovium, has recently been shown to
also be citrullinated. It is thus possible that AKA, AFA, APF, and
anti-Sa all recognize one or more citrullinated antigens. Despite
this possibility, the modest degree of concordance between
them in individual patient sera suggests that it is unlikely that a
single antigen is involved in generating these responses.
This study provides evidence suggesting that anti-Sa
antibodies appear to be a marker for a subset of early RA
patients whose disease may be more severe and erosive.
Moreover, it was determined that anti-Sa, AFA, and anti-CCP
were all highly associated with SE, particularly two copies. We
examined a spectrum of potential RA severity indicators
including the number of swollen joints, CRP level, and
presence of early radiographic erosions. Our data indicate that
anti-Sa was more highly associated with these measures of RA
severity than any other parameter, including the most accepted
prognostic indicators, RF and SE.
In conclusion, it is demonstrated that antibodies directed
against putatively citrullinated antigens including Sa, filaggrin,
keratin, and CCP are the most specific for RA, and are
detectable early in the disease course. It will be of interest to
find out whether the cumulative prevalence of specific
autoantibody subsets tends to increase over time, as this
would suggest that the mechanisms underlying the
development of these reactivities continue to evolve over the
course of the arthropathy.
Introduction
Autoantibodies can be detected in a spectrum of
rheumatic diseases where they may be highly associated
with distinct clinical syndromes. These are often helpful for
diagnosis, and to some extent, prognosis. In RA, RF is
detected in 70–80% of patients with established disease,
and is an integral part of the definition of this disorder.
AKA, APF , AFA, and anti-Sa have all been shown to be
associated with RA, and appear to be more specific than
RF for this disease [1–9]. Anti-RA-33, [10–12] and
anti-RA-1 [13] have also been shown to be prevalent in
RA patient populations, but not specific for this disease.
There is an evolving understanding of the antigens to which
these RA associated antibodies are directed, although their
ultimate pathogenic role, if any, continues to be unclear.
AKA, APF, and AFA identify epitopes carried by keratin,
profilaggrin and filaggrin, respectively [3,6,14,15]. These
proteins follow a common post-translational pathway,
which involves a peptidyl-arginine to citrulline deimination.
This modification appears to be central to specific anti-
genicity, giving rise to epitopes recognized by sera from
RA patients [16,17]. Anti-Sa antibodies are directed
towards an unknown antigen that is abundant in placental
tissue and rheumatoid synovium [7]. Interestingly, the Sa
antigen also appears to be citrullinated [18]. Anti-RA-33
antibodies recognize the A2 protein, an antigen found in
the heterogeneous ribonucleoprotein of the splicosome
[19]. Anti-RA-1 antibodies are directed towards domains 3
and 4 of calpastatin, the natural inhibitor of calpains, which
Full article
Table 2
Association of autoantibodies with shared epitope (SE) alleles
SE/x SE/SE *0401/*0101
All patients
RF 1.8 3.7* 8.7*
AFA 2.2* 5.1* 9.5*
Anti-Sa 2.0 7.1* 18.9*
Anti-CCP 2.0 5.0* 10.9*
AKA 1.4 3.1* 3.4*
RA patients
RF 1.8 2.7 5.3
AFA 2.2 4.9* 6.5*
Anti-Sa 1.9 4.0* 10.6*
Anti-CCP 2.0 3.0 7.2*
AKA 1.4 2.9 3.3
Numbers represent odds ratios for having each autoantibody
associated with shared epitope alleles. SE/x, SE/SE, DRB
*0401/*0101 were each compared with patients with no shared
epitope alleles. * P < 0.05 by Chi-square after Bonferroni adjustment
for multiple comparison. RF, Rheumatoid factor; AFA, antifilaggrin
antibody; CCP, cyclic citrullinated peptide; AKA, antikeratin antibody.are members of the cysteine proteinases that have been
implicated in articular damage [13].
This spectrum of autoantibodies has been evaluated pri-
marily in cohorts of patients with well-established RA. A
number of important questions are unresolved regarding
the stage of the disease at which each of these antibodies
arise, and whether indeed some may antedate the clinical
expression of this disorder. The fact that RF, AKA or APF
could sometimes antedate the appearance of clinical RA
by several years has been reported [20–22]. Anti-Sa, AFA
and anti-RA-33 have been reported to be present in early
RA patients, although the cohorts studied have generally
been small, and the clinical characterization of the patients
not detailed [1,8,9,23,24]. Anticyclic citrullinated peptide
(anti-CCP) has recently been evaluated in a cohort of
patients with early synovitis, and was found to be more
specific than RF for early RA, while having comparable
sensitivity [25].
Recently, the clinical features and human leukocyte
antigen (HLA) associations of a well-characterized cohort
of patients with synovitis of recent onset were presented
[26]. In the current study, we sought to determine the
prevalence and diagnostic value of the RA associated
autoantibodies in this heterogeneous cohort of patients
with early synovitis. Sera obtained within 12 months of
symptom onset were tested for these antibodies, and their
presence was related to disease features and subsequent
clinical course over a 1 year period. Our data indicate that
AFA, anti-Sa, and anti-CCP are all highly specific for early
RA, but demonstrate only a modest degree of concor-
dance in the sera of individual patients. Anti-Sa identifies a
subset of male RA patients with severe disease.
Methods
Patients
Two hundred and thirty-eight patients were recruited to an
early synovitis study at the National Institutes of Health
(protocol 94-AR-194). The study patients had persistent
synovitis (>6 weeks) of at least one peripheral joint, which
had been present for less than 1 year. Patients with trau-
matic, septic, and crystal induced arthritis were specifi-
cally excluded.
Patients underwent a complete clinical evaluation. The
number of swollen joints was determined by evaluating for
the presence of effusion and/or synovial thickening in 66
peripheral joints (hips were excluded). Patients were then
followed clinically over a 1 year period. Routine laboratory
data were obtained on each visit, including an evaluation
of acute phase reactants. Anteroposterior and lateral
radiographs of the hands and feet were either available for
evaluation or obtained at the time of assessment. A
second set of radiographs was obtained at the 1 year visit.
All radiographs were evaluated for the presence of
erosions. Although a proportion of the radiographs were
felt to have ‘possible’ or ‘questionable’ erosions, only
patients with definite erosions on either set of radiographs
were included in the definition of erosions. At the comple-
tion of the year of observation, patients who were diag-
nosed as having RA had all met the 1987 American
College of Rheumatology (ACR) criteria [27] on at least
one visit. If a patient had met ACR criteria, but with follow
up was unequivocally diagnosed as having another well-
characterized rheumatic disease, this individual was not
included in the definition of RA.
Detection of autoantibodies
IgM RF was measured by nephelometry, and a level
>20IU/ml was considered positive. Anti-Sa antibodies
were detected by immunoblot, as previously described
[7]. A partially purified preparation of placental Sa antigen
was provided by one of the authors (HAM), and the
western blot assay performed blindly by another (GS).
RA-33 was detected using immunoblot, as described pre-
viously [19]. Filaggrin was obtained from human epidermis
and purified using reversed phase high-performance liquid
chromatography. After covalently coupling to 96-well
plates, AFA were detected by enzyme-linked immunosor-
bent assay (ELISA) as previously described [1,5]. The cut-
off level for positivity (OD, 0.15) was determined on the
basis of results of sera from 100 middle-aged (40–65
years) blood donors. Antibodies to CCP were evaluated
after generating a cyclic peptide from linear citrulline con-
taining peptides, by substituting serine residues by cys-
teine. Anti-CCP were detected using ELISA as previously
described with the linear peptides [17]. Control peptides
had an unmodified arginine rather than citrulline. The cut-
off level for positivity (OD, 0.3) was determined on the
basis of generating 100% specificity for RA in previous
assays using local normal controls. AKA were detected
using immunoflurescence. Sections of human breast epi-
dermis were used, and the slides were read independently
by two observers (AR and CZ). Any slides in which the
observers did not agree were reread, and a consensus
agreed. In all cases, the detected autoantibodies were of
the IgG class. The results were not corrected for total IgG
levels.
HLA typing
HLA-DR typing was done by the molecular polymerase
chain reaction-sequence specific primers method using
specific oligonucleotide sequences as primers as previously
described [28]. Shared epitope (SE) alleles included
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001,
*1402.
Statistical analysis
Patient groups were compared using analysis of variance or
the Kruskal–Wallis test for continuous variables, and using
the Chi-squared test for proportions. The significance level
http://arthritis-research.com/content/2/3/236for associations between individual autoantibodies and
HLA-DRB1 alleles was adjusted for multiple comparisons
using the Bonferroni method. Statistical analysis was per-
formed using EpiInfo statistical software (Center for Disease
Control, Atlanta, GA, USA: http://www.cdc.gov/epo/epi/
epiinfo.htm).
Results
Of the 238 patients with synovitis of recent onset in the
cohort, 106 (45%) met RA criteria, 102 (96%) of whom
met the criteria on their initial visit. Four patients initially
met RA criteria, but were given nonRA diagnoses on
follow up. Two of these patients had SLE, and two had
psoriatic arthritis. All four presented with RF– polyarthritis.
Diagnoses in the remaining nonRA patients included 22
(9%) with reactive arthritis, 14 (6%) with psoriatic arthritis
or another form of spondylarthropathy, 11 (5%) with
another well-defined rheumatic diagnosis, and 85 (36%)
with undifferentiated arthritis. The clinical characteristics
of the RF-positive (RF+) RA, RF-negative (RF–) RA and
nonRA patients are summarized in Table 1.
Prevalence of the autoantibodies in the patient cohort
Table 1 indicates the prevalence of a spectrum of known
autoantibodies and of the RA associated antibodies in
patients diagnosed as having RF+ RA, RF– RA, and
nonRA. In total, 87 patients were RF-positive, 17 of whom
did not meet RA criteria any point during the study period,
and were classified as having undifferentiated arthritis. Anti-
nuclear antibodies were detected in 65/238 (27%)
patients, and were of comparable prevalence in the patient
groups. Less than 10% of the patients in all groups demon-
strated antibodies to SSA, SSB, dsDNA, ribonucleoprotein
(RNP), and Sm. Of the RA associated antibodies tested,
AFA, anti-Sa, anti-CCP, and AKA were all significantly
more prevalent in the RF+ RA group compared with either
the RF– RA group or the nonRA group. Anti-RA-1 antibod-
ies were detected in 35% of the cohort with no significant
difference between the groups. Anti-RA-33 antibodies
were detected in three patients in the cohort. Please note,
the prevalence of anti-Sa antibodies was significantly
higher in the RF– RA group compared with the nonRA
group (14% versus 2%; P<0.01), but there were no differ-
ences in the prevalence of the other autoantibodies
between these two patient groups. In total, 90/106 (85%)
of the RA patients and 75/132 (57%) of the nonRA
patients had at least one of the RA associated antibodies.
Diagnostic value of antibodies for RA
The diagnostic value of the individual antibodies for RA is
shown in Table 3. RF had the highest sensitivity at 66%,
and all the other antibodies were individually less than
50% sensitive. AFA, anti-Sa and anti-CCP were greater
than 90% specific for RA, while RF and AKA were
80–90% specific, and anti-RA-1 was not specific for this
diagnosis. The data further indicate that adding any one of
AFA, AKA, anti-Sa, or anti-CCP to RF increases the speci-
ficity for RA from 80 to 90%. In the absence of RF, the
presence of one or more of these antibodies carried a
sensitivity of only 31% for RF– RA, with anti-Sa being the
most specific at 98%. At the completion of the study, of
the 37/132 (28%) nonRA patients positive for one of AFA,
AKA, anti-Sa, or anti-CCP, 12 had some form of spondy-
larthropathy, 4 had a connective tissue disease, and 21
continued with a diagnosis of ‘undifferentiated arthritis’.
Correlation between antibodies in patient sera
Previous studies have generally suggested a high degree
of correlation in RA patient sera between AFA, AKA,
anti-CCP, and anti-Sa. We tested the correlation between
these antibodies in the patient sera. The correlation was
highest between anti-CCP and anti-Sa [odds ratio (OR),
13.3; P<0.001), and lowest between anti-Sa and AKA
(OR, 2.4; P=0.09). In total, 101 patients had at least one
of the four antibodies, 64% of whom had RA. Of these
101 patients, 57 were in fact positive for only one anti-
body (AKA=20, AFA=12, anti-Sa=6, anti-CCP=19).
Only seven patients were positive for all four antibodies.
Seropositivity for anti-CCP and AFA was determined on
the basis of an ELISA cut-off level as described in the
Methods section. The relationship between the titers of
these two antibodies, and between each of them and RF,
was examined. There was a significant correlation in the
titers of anti-CCP and AFA in individual sera (r=0.46;
P<0.001). Titers of both anti-CCP and AFA were not cor-
related with RF titers. When only anti-CCP-positive
patients were examined, the mean CCP titer was signifi-
cantly higher in the RF-positive patients (n=44) compared
with the RF-negative patients (n=10) (1.07±0.55 versus
0.6±0.34; P=0.01). A similar trend was seen with AFA,
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Table 3
Diagnostic value of individual autoantibodies for rheumatoid
arthritis
Sensitivity Specificity PPV NPV Accuracy
RF 0.66 0.87 0.80 0.76 0.78
AFA 0.33 0.93 0.79 0.63 0.66
Anti-Sa 0.22 0.98 0.88 0.61 0.64
Anti-CCP 0.41 0.91 0.78 0.66 0.69
AKA 0.26 0.84 0.56 0.58 0.58
RF+ and one 0.50 0.96 0.90 0.70 0.75
or more*
RF– and one 0.31 0.73 0.26 0.77 0.63
or more*
* Includes antifilaggrin antibody (AFA), anti-Sa, cyclic citrullinated
peptide (anti-CCP) and antikeratin antibody (AKA). PPV, positive
predictive value; NPV, negative predictive value; RF, rheumatoid factor.although this did not reach statistical significance. Of note
also, the mean RF titer for RF-positive patients who did
not meet RA criteria did not differ from the RF-positive
patients who were diagnosed as having RA (202±172
versus 207±169; P=not significant).
RF, Sa, AFA, and CCP are highly associated with shared
epitope in early RA
RA has been shown in multiple populations to be associ-
ated with HLA-DR alleles encoding for the SE. We sought
to determine if specific autoantibodies were particularly
associated with SE alleles in our cohort. These data are
presented in Table 2. Overall, the SE alleles were highly
associated with the diagnosis of RA (OR 3.0; P<0.0001).
RF, AFA, anti-Sa, and anti-CCP were all associated with
SE alleles, particularly two copies. Interestingly, 6/6
patients with *0101/*0401 were positive for at least one
these autoantibodies.
Anti-Sa antibodies identify a male predominant subset of
RA patients with severe disease
Table 4 demonstrates that, in comparison with all other RA
patients, RA patients with anti-Sa antibodies were pre-
dominantly male (61% versus 28%; P<0.01), had signifi-
cantly higher swollen joint counts (18±12 versus 13±9;
P=0.02), and higher CRP levels (2.6±3mg/dl versus
1.6±1.4mg/dl;  P=0.03) at the initial visit. Despite subse-
quently being treated with significantly higher doses of
prednisone (4.8±6.0mg/day versus 1.8±3.3mg/day;
P<0.01), and more disease modifying antirheumatic drug
therapy (1.4±0.8 versus 0.9±0.7 disease modifying
antirheumatic drugs; P<0.01), the anti-Sa-positive RA
patients had a higher frequency of erosions than the rest
of the RA patients (60% versus 33%; P = 0.03). Table 4
further indicates that neither RF nor SE was associated
with the disease severity measures, and analyses evaluat-
ing all the other autoantibodies failed to reveal a similar
trend (data not shown). Of interest, only six RA patients
demonstrated the presence of nodules, and this feature
was more associated with RF and SE than with anti-Sa.
Analysis of the nonRA patients did not reveal any clinically
meaningful associations with any of the autoantibodies.
Discussion
A cohort of patients with synovitis of recent onset was
evaluated and we sought to determine the prevalence and
potential clinical utility of a spectrum of autoantibodies
that has been shown to be associated with RA. To date,
most of the studies evaluating these antibodies have been
in patients with established, well-characterized disease,
and their prevalence and diagnostic value in patients with
early inflammatory arthritis has not been defined. Our
study evaluated patients within a few months of the onset
of synovitis, and then followed them for a 1 year period to
determine the best clinical diagnosis. In particular, we
sought to determine how sensitive and specific each of
http://arthritis-research.com/content/2/3/236
Table 4
Sa is associated with severe rheumatoid arthritis (RA)
Sa+ RA Sa– RA RF+ RA RF– RA SE+ RA SE– RA
(n = 23) (n = 83) (n = 70) (n = 36) (n = 62) (n = 44)
Male (%) 14 (61)* 23 (28) 27 (39) 10 (28) 24 (39) 13 (30)
Age  48 ± 15 46 ± 13 47 ± 12 44 ± 15 49 ± 13* 42 ± 13
Duration of symptoms 36 ± 25 30 ± 18 33 ± 17 29 ± 24 32 ± 15 31 ± 25
(weeks)
Initial visit
Swollen joints 18 ± 12* 13 ± 9 13 ± 9 16 ± 10 13 ± 9 14 ± 11
Nodules 1 (4) 5 (6) 5 (7) 1 (3) 5 (8) 1 (2)
CRP (mg/dl) 2.6 ± 3* 1.6 ± 1.4 1.9 ± 1.8 1.9 ± 2.1 1.7 ± 1.5 2.1 ± 2.4
On DMARDs (%) 11 (48) 31 (37) 28 (40) 14 (39) 24 (39) 18 (41)
On prednisone (%) 12 (52) 29 (35) 25 (36) 16 (44) 26 (42) 15 (34)
Multiple erosions (%)† 7 (30) 12 (14) 12 (17) 7 (19) 12 (19) 7 (16)
One year visit
Swollen joints  8 ± 9 8 ± 10 9 ± 11 7 ± 7 10 ± 11* 5 ± 6
CRP (mg/dl) 1.1 ± 0.7 1.2 ± 1.8 1.3 ± 1.9 0.9 ±0.5 1.4 ± 2.1 0.9 ± 0.3
Number of DMARDs 1.4 ± 0.8* 0.9 ± 0.7 0.9 ± 0.7 1.0 ± 0.8 0.9 ± 0.7 1.1 ± 0.8
Prednisone (mg/day) 4.8 ± 6.0* 1.8 ± 3.3 2.7 ± 4.8 2.0 ± 2.5 2.7 ± 4.0 2.1 ± 3.9
Multiple erosions (%)† 12 (60)* 27 (33) 24 (34) 14 (39) 25 (42) 13 (30)
Inactive disease (%) 0 9 (12) 3 (4) 6 (17) 4 (7) 5 (11)
Independent comparisons are made between Sa+ and Sa– RA, RF+ and RF– RA, SE+ and SE– RA. * P < 0.05. † One hundred and two out of
106 (96%) of the patients had 1 year radiographs available for analysis. Multiple erosions included all patients with two or more erosions that
involved at least two separate joint areas. RF, Rheumatoid factor; SE, shared epitope; CRP, C-reactive protein; DMARD, disease modifying
antirheumatic drug.Arthritis Research    Vol 2 No 3 Goldbach-Mansky et al
the antibodies, alone and in combination, were for early
RA. We utilized the accepted definition of RA using the
1987 ACR criteria [27]. Of note, a large epidemiologic
study of patients with early inflammatory arthritis found
that the proportion of patients who met the ACR criteria
increased if the criteria were applied cumulatively over a 5
year period [29]. Although the duration of follow up in this
study was shorter, we found that almost all of the patients
who had met the RA criteria at the completion of the study
period had done so on their initial visit.
Despite a well-documented lack of specificity, RF continues
to be a central part of the definition of RA, primarily because
of its favorable sensitivity profile. In our cohort, RF had a
sensitivity of 66%, a specificity of 87%, and an overall accu-
racy of 78% for the diagnosis of RA. AFA, anti-Sa and
anti-CCP were all highly specific for this diagnosis, and
when any of them were present in conjunction with RF, the
specificity for RA approached 100%. Potentially of more
importance to the clinician is the diagnostic value of these
antibodies when RF is not detectable. Our data indicate
that only 31% of RF– RA patients had any of AKA, AFA,
anti-Sa or anti-CCP, and that anti-Sa was the most specific
for this diagnosis. This modest level of sensitivity suggests
that testing for this spectrum of autoantibodies carries little
advantage over RF alone in diagnosing early RA.
This study provides evidence suggesting that anti-Sa anti-
bodies appear to be a marker for a subset of early RA
patients whose disease may be more severe and erosive.
These data are consistent with observations in a French
RA cohort, where anti-Sa and SE were associated with
severe radiographic erosions [9]. Indeed, it was deter-
mined that anti-Sa, AFA, and anti-CCP were all highly
associated with SE, particularly two copies. We examined
a spectrum of potential RA severity indicators including
the number of swollen joints, CRP level, and presence of
early radiographic erosions. Our data indicate that anti-Sa
was more highly associated with these measures of RA
severity than any other parameter, including the most
accepted prognostic indicators, RF and SE. In particular,
there was a significantly higher prevalence of radiographic
erosions in the anti-Sa-positive RA patients compared
with the rest of the RA population, despite the fact that the
anti-Sa-positive patients had received significantly higher
doses of prednisone and more disease modifying
antirheumatic drug therapy. Interestingly, the anti-Sa-posi-
tive subset in this cohort was strikingly predominated by
males (61% of Sa-positive versus 28% of Sa-negative RA
patients; P<0.001). It has recently been shown that, in
comparison with female RA patients, male RA patients
tended to develop erosions earlier in the disease course
[30]. The finding that anti-Sa antibodies are associated
both with male gender and with severe early RA further
emphasizes the importance of gender differences in the
clinical expression of this heterogeneous disease.
AFA, AKA, and APF have been proposed to all identify a
common antigen present in the skin protein (pro)filaggrin
[1,3–6]. It has continued to be puzzling why a skin antigen
would be targeted relatively specifically in a disorder that
is primarily articular. A potential explanation for this may
relate to the demonstration that citrulline appears to be an
essential constituent of the antigenic determinants recog-
nized by AKA, APF, and AFA [16,17]. The citrulline rich
(pro)filaggrin molecule makes an ideal substrate for
detecting this reactivity. Moreover, the Sa antigen, which,
unlike (pro)filaggrin, is detectable in rheumatoid synovium,
has recently also been shown to be citrullinated [18]. It is
thus possible that AKA, AFA, APF, and anti-Sa all recog-
nize one or more citrullinated antigens. As with previous
studies, the current study documents a good overall corre-
lation between these antibodies. Nevertheless, the data
clearly indicate that reactivity to CCP does not capture the
complete spectrum of AFA, AKA, and anti-Sa reactivity.
Indeed, it has been shown that 56% of patients who were
positive for one or more of these antibodies were positive
for only one, and that only 7% of these patients were posi-
tive for all of them. Similarly, previous studies evaluating
AKA, APF, and AFA have shown varying degrees of dis-
cordance in the seropositivity of individual patient sera
[3–5,14]. Moreover, there was a spectrum of reactivity
patterns seen when RA sera were tested against various
citrulline containing peptides [17]. Together, these data
are most consistent with the hypothesis that individual RA
patients respond to unique antigenic determinants, that
may preferentially be citrullinated, but that are likely dis-
tinct from those of targeted by other RA patients.
It was surprising to discover that anti-RA-33 antibodies
were all but absent in this cohort of patients, particularly in
view of the previously reported prevalence of 20–40% in
other RA cohorts [10–12]. This antibody was reported to
have a prevalence of only 6% in a Finnish cohort of early
RA patients [24]. It should be pointed out that the testing
for anti-RA-33, including that performed in the current
study, was all performed in the same laboratory (GS). The
reasons for this discrepancy are unclear, and may repre-
sent inherent differences in the populations studied. Alter-
natively, it is possible that the development of anti-RA-33
reactivity increases as the disease progresses. Longitudi-
nal follow up of early RA cohorts, such as the present one,
will help to further clarify this issue.
In the current study, it was demonstrated that antibodies
directed against putatively citrullinated antigens including
Sa, filaggrin, keratin, and CCP are the most specific for
RA, and are detectable early in the disease course. It will
be of interest to find out whether the cumulative preva-
lence of specific autoantibody subsets tends to increase
over time, as this would suggest that the mechanisms
underlying the development of these reactivities continue
to evolve over the course of the arthropathy.http://arthritis-research.com/content/2/3/236
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